Prelude Enterprise Value Over E B I T D A from 2010 to 2024
| PRLD Stock | USD 0.98 0.02 2.08% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.90) | Current Value (2.00) | Quarterly Volatility 23.85616823 |
Check Prelude Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prelude Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 821.5 K, Interest Expense of 1.6 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.14. Prelude financial statements analysis is a perfect complement when working with Prelude Therapeutics Valuation or Volatility modules.
Prelude | Enterprise Value Over E B I T D A |
Latest Prelude Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Prelude Therapeutics over the last few years. It is Prelude Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Prelude Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Prelude Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (39.47) | |
| Coefficient Of Variation | (60.44) | |
| Mean Deviation | 20.86 | |
| Median | (55.68) | |
| Standard Deviation | 23.86 | |
| Sample Variance | 569.12 | |
| Range | 53.7831 | |
| R-Value | 0.83 | |
| Mean Square Error | 191.96 | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 4.42 | |
| Total Sum of Squares | 7,968 |
Prelude Enterprise Value Over E B I T D A History
About Prelude Therapeutics Financial Statements
Prelude Therapeutics stakeholders use historical fundamental indicators, such as Prelude Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Prelude Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prelude Therapeutics' assets and liabilities are reflected in the revenues and expenses on Prelude Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prelude Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (1.90) | (2.00) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out the analysis of Prelude Therapeutics Correlation against competitors. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.